Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loteprednol Etabonate for Inflammation Following Cataract Surgery
NCT00699153Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Jun 2008
- Primary completion
- May 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of loteprednol etabonate ophthalmic gel 0.38% in ocular inflammation (2 arms), sponsored by Bausch + Lomb. Primary endpoints: Participants With Complete Resolution of Anterior Chamber Cells and Flare at Day 8 and Participants With Grade 0 (no) Pain at Day 8. Started Jun 2008; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT00699153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00699153.